Unlocking the potential of K-RAS inhibitors
At AACR 2022 (8th–13th April) in New Orleans (LA, USA), we caught up with Kevan Shokat, Professor at the University of California, San Francisco (UCSF; CA, USA), and Investigator at Howard Hughes Medical Institute (MD, USA). K-RAS was the first human oncogene discovered; however, for decades researchers struggled to find a binding pocket for inhibitors to bind to it. K-RAS was thought to be an undruggable oncogene, until finally in 2013, Kevan Shokat and his team made a discovery that opened the K-RAS-inhibitor floodgates. In this interview, we chat to Kevan about his prize-winning discovery and the bespoke technique that...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
